Vaccine最新文献

{"title":"Partnering with social media influencers to promote HPV vaccination in diverse communities","authors":"Amy E. Leader ,&nbsp;Amelia Burke-Garcia ,&nbsp;Dasha Afanaseva ,&nbsp;Erin Cutroneo ,&nbsp;Preethi Selvan ,&nbsp;Kayla Madden ,&nbsp;Joshua Banks ,&nbsp;Angela Sustaita-Ruiz","doi":"10.1016/j.vaccine.2025.127085","DOIUrl":"10.1016/j.vaccine.2025.127085","url":null,"abstract":"<div><h3>Background</h3><div>While human papillomavirus (HPV) vaccination is one of the most effective ways to prevent HPV-related cancers, many children and adolescents remain unvaccinated. Resistance often stems from parental vaccine hesitancy and mistrust of the health care system, both of which may be higher in communities of color. Partnering with social media influencers may be an effective method for disseminating health messages. We tested the impact of HPV social media posts developed by influencers on outcomes of knowledge, attitudes, and intentions to vaccinate.</div></div><div><h3>Methods</h3><div>Ten social media influencers who identified as African American or Hispanic created posts about the HPV vaccine. Next, influencers recruited followers to complete a baseline survey, view the post, and complete an endpoint survey. We measured changes in knowledge, attitudes, and intentions to vaccinate their children against HPV. We also captured trust in the influencer and perceptions of the post. Mean scores or frequencies were calculated; changes from baseline to endpoint were assessed with repeated measures <em>t</em>-tests.</div></div><div><h3>Results</h3><div>Of ten social media influencers, four were African American and six were Hispanic; all were female and eight were married. Seven influencers indicated Instagram as their preferred platform; seven posted daily. The influencers recruited 134 followers (86 % female, 56 % non-Hispanic Black, 24 % Hispanic) who, on average, had been following their influencer for 1 to 3 years. We observed significant increases in knowledge of HPV and the vaccine (<em>p</em> &lt; 0.001), attitudes towards vaccinating against HPV (p &lt; 0.001), and intentions to vaccinate (p &lt; 0.001) after viewing a post created by an influencer.</div></div><div><h3>Discussion</h3><div>As public health professionals struggle to reach key audiences, social media influencers may be powerful opinion leaders, especially where mistrust of traditional institutions is high.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 127085"},"PeriodicalIF":4.5,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccination uptake in people experiencing homelessness during the first three years of the global COVID-19 vaccination effort: A systematic review and meta-analysis","authors":"Laura K. McCosker ,&nbsp;Brett Dyer ,&nbsp;Terra Sudarmana ,&nbsp;Holly Seale ,&nbsp;Robert S. Ware","doi":"10.1016/j.vaccine.2025.127050","DOIUrl":"10.1016/j.vaccine.2025.127050","url":null,"abstract":"<div><div>There are complex barriers to vaccination, including COVID-19 vaccination, in people experiencing homelessness. Consequently, it is likely COVID-19 vaccination uptake in this vulnerable population is lower than in general populations. This systematic review and meta-analysis reports COVID-19 vaccination uptake in people experiencing homelessness, including in comparison to general populations, in literature published during the first three years of the global COVID-19 vaccination effort.</div><div>Searches were conducted on eight electronic databases. Peer-reviewed studies from high-income countries available in English and in full-text were considered for inclusion. Studies were considered up to 31 December 2023.</div><div>In total 1884 studies were retrieved and, after removal of duplicates, 1167 were screened. Thirty-one studies were included in this review. For studies reporting uptake of either any, or first, COVID-19 vaccine a random effects meta-analysis was used to pool coverage estimates. It included 28 first vaccine dose coverage estimates from 18 studies including 104,139 vaccinated individuals in 308,253 participants. The pooled estimate for first dose vaccine coverage in people experiencing homelessness was 43 % (95 % CI: 35 %, 51 %). The 95 % prediction interval was (0, 88 %). Uptake of subsequent doses was heterogeneous and was reported narratively. Uptake of the second dose ranged upwards from 31.3 %, and uptake of the third dose was reported in one study as 7.2 %.</div><div>COVID-19 vaccination uptake in people experiencing homelessness is lower than in general populations. Disparities in uptake persisted when comparing uptake at regional/state/national levels, at multiple timepoints, and in studies focused on different sub-populations including veterans. This is problematic, considering people experiencing homelessness are more likely to have poorer COVID-19-associated outcomes. It is important to recognise people experiencing homelessness are an at-risk, hard-to-reach group for vaccination, and vaccination strategies should be targeted to this population to improve uptake.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 127050"},"PeriodicalIF":4.5,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143769213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring TLR agonists as adjuvants for COVID-19 oral vaccines","authors":"Paulo Félix ,&nbsp;Alexandra A. Melo ,&nbsp;João Panão Costa ,&nbsp;Mariana Colaço ,&nbsp;Dina Pereira ,&nbsp;Jisette Núñez ,&nbsp;Luís Pereira de Almeida ,&nbsp;Olga Borges","doi":"10.1016/j.vaccine.2025.127078","DOIUrl":"10.1016/j.vaccine.2025.127078","url":null,"abstract":"<div><div>The COVID-19 pandemic underscored the importance of advancing technologies that enable the rapid development and distribution of more effective vaccines when required. Since SARS-CoV-2 enters the body through the nasal mucosa, optimising the induction of secretory IgA (sIgA) production, a key component of the mucosal immune response, is essential. It has long been known that the induction of sIgA occurs when a vaccine is administered through mucosal surfaces and the immune responses initiated at one mucosal site can influence immune activity at other mucosal surfaces. Consequently, we propose an oral vaccine formulation (Vacform) comprising the immunomodulator CL097, a TLR7/8 agonist, and the SARS-CoV-2 spike protein, both encapsulated within glucan particles (GPs). The studies demonstrated that Vacform induced ROS production in RAW 264.7 cells but not in human neutrophils. The concentrations of Vacform tested did not induce NO production in RAW 264.7 cells. While Vacform stimulated the production of TNF-α and IL-6 in mouse spleen cells, this effect was not observed in RAW 264.7 cells. Finally, Vacform stimulated the proliferation of human PBMCs. Thus, its immunomodulatory properties were evident in specific cells under certain in vitro conditions. The Vacform was subsequently tested in vaccination studies. C57BL/6 mice were initially immunized subcutaneously, followed by two oral boosts with Vacform every two weeks. The Vacform elicited both, humoral (serum IgG and mucosal sIgA) and cellular immune responses. A balanced Th1/Th2/Th17 immune profile was observed. In conclusion, the GPs:CL097 adjuvant system shows promise for eliciting robust immune responses against SARS-CoV-2 and provides a foundation for future studies on dose-response optimization and challenge models.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 127078"},"PeriodicalIF":4.5,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of 2023–2024 COVID-19 vaccines against COVID-19–associated hospitalizations among adults aged ≥18 years with end stage kidney disease — United States, September 2023–April 2024","authors":"Amanda B. Payne ,&nbsp;Shannon Novosad ,&nbsp;Heng-Ming Sung ,&nbsp;Yue Zhang ,&nbsp;Ryan Wiegand ,&nbsp;Carla S. Gomez Victor ,&nbsp;Megan Wallace ,&nbsp;Danica J. Gomes ,&nbsp;Morgan Najdowski ,&nbsp;Bradley Lufkin ,&nbsp;Yoganand Chillarige ,&nbsp;Eduardo Lacson ,&nbsp;Lorien S. Dalrymple ,&nbsp;Ruth Link-Gelles","doi":"10.1016/j.vaccine.2025.127010","DOIUrl":"10.1016/j.vaccine.2025.127010","url":null,"abstract":"<div><h3>Background</h3><div>Persons with end stage kidney disease (ESKD) on dialysis are at high risk for severe COVID-19 disease. In September 2023, 2023–2024 COVID-19 vaccination was recommended in the United States for all persons aged ≥6 months. Due to possible immune dysfunction, advanced age, and high prevalence of additional underlying conditions, including immunocompromising conditions, among individuals with ESKD, reduced vaccine effectiveness (VE) is a concern. Understanding effectiveness of 2023–2024 COVID-19 vaccine among persons with ESKD can inform COVID-19 vaccine recommendations for this population.</div></div><div><h3>Methods</h3><div>A retrospective cohort investigation was conducted among Medicare fee-for-service beneficiaries aged ≥18 years with ESKD receiving dialysis using Medicare enrollment and claims records. Follow-up began on September 17, 2023, and continued until the earliest occurrence of claim for a COVID-19–associated outcome, other censoring event, or end of follow-up. A marginal structural Cox model was used to estimate VE (calculated as [1 – hazard ratio]*100 %), interpreted as the benefit of 2023–2024 COVID-19 vaccination compared with no 2023–2024 vaccine dose. VE was estimated by presence of additional immunocompromising conditions, age group, and time since vaccination.</div></div><div><h3>Results</h3><div>During September 17, 2023 – April 13, 2024, 17,749/112,250 (16 %) Medicare beneficiaries aged ≥18 years with ESKD without additional immunocompromising conditions received a 2023–2024 COVID-19 vaccine dose, with a maximum 209 days of follow-up since vaccination. During the follow-up period 6539 medically attended COVID-19 events, including 3605 COVID-19-associated hospitalizations, 789 COVID-19-associated deaths, and 896 COVID-19-associated thromboembolic events, were recorded. VE against COVID-19-associated hospitalization was 55 % (95 % confidence interval [CI]: 42 % - 65 %) at 7–59 days after vaccination and 47 % (95 % CI: 35 % – 57 %) at ≥60 days after vaccination. VE against COVID-19-associated death was 71 % (95 % CI: 46 % - 84 %) at 7–59 days after vaccination and 51 % (95 % CI: 24 % – 69 %) ≥60 days after vaccination. VE against COVID-19-associated thromboembolic events was 44 % (95 % CI, 24 %, 59 %).</div></div><div><h3>Conclusions</h3><div>The 2023–2024 COVID-19 vaccines provided protection against COVID-19-associated hospitalization, death, and thromboembolic events among adults with ESKD. These data support the recommendation that adults with ESKD receive the updated COVID-19 vaccine.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127010"},"PeriodicalIF":4.5,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to the article titled, “Attitudes and beliefs about vaccination among adults in the United States: A real-world, cross-sectional, web-based survey study” [Vaccine 50 (2025) 126807]","authors":"Amanda L. Eiden ,&nbsp;deMauri S. Mackie ,&nbsp;Kushal Modi ,&nbsp;Sheila Drakeley ,&nbsp;Amanda R. Mercadante ,&nbsp;Alexandra Bhatti ,&nbsp;Anthony DiFranzo","doi":"10.1016/j.vaccine.2025.127053","DOIUrl":"10.1016/j.vaccine.2025.127053","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 127053"},"PeriodicalIF":4.5,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial","authors":"Gonzalo Perez Marc ,&nbsp;Lorena M. Coria ,&nbsp;Ana Ceballos ,&nbsp;Juan Manuel Rodriguez ,&nbsp;Mónica E. Lombardo ,&nbsp;Laura Bruno ,&nbsp;Federico Páez Córdoba ,&nbsp;Clara G. Fascetto Cassero ,&nbsp;Melina Salvatori ,&nbsp;Mayra Rios Medrano ,&nbsp;Fabiana Fulgenzi ,&nbsp;María F. Alzogaray ,&nbsp;Analía Mykietiuk ,&nbsp;Ignacio Leandro Uriarte ,&nbsp;Nicolás Itcovici ,&nbsp;Tomás Smith Casabella ,&nbsp;Gonzalo Corral ,&nbsp;Miriam Bruno ,&nbsp;Oscar Roldán ,&nbsp;Sebastián A. Núñez ,&nbsp;Juliana Cassataro","doi":"10.1016/j.vaccine.2025.127045","DOIUrl":"10.1016/j.vaccine.2025.127045","url":null,"abstract":"<div><div>A randomized, placebo-controlled, crossover, double-blind, phase II/III study was conducted to evaluate the immunogenicity, safety, and tolerability of a recombinant booster vaccine (ARVAC) containing the SARS-CoV-2 spike protein receptor binding domain in three versions: ARVAC_Gamma, ARVAC_Omicron, and ARVAC_Bivalent in adults with ≤3 previous SARS-CoV-2 booster doses. Primary endpoint was seroconversion rate of neutralizing antibodies compared to placebo and to a &gt; 75 % seroconversion rate to vaccine antigen homologous variants. All vaccine versions significantly increased seroconversion rates to SARS-CoV-2 variants compared to placebo. In participants aged 18–60 years, all versions met the primary endpoint; in those over 60 years old, ARVAC_Omicron and ARVAC_Bivalent met this endpoint. No vaccine-related serious adverse events were recorded, and most adverse events were mild. Plasma levels of anti-spike-specific IgG and anti-S1-specific IgA in saliva increased in participants receiving any vaccine. The increase in plasma neutralizing antibodies induced by the vaccine was independent of the number of previous booster doses (0, 1 or 2), the primary vaccine platform (adenovirus, single-dose adenovirus, mRNA, inactivated virus, heterologous vaccination, and virus-like particle [VLP]) and the history of previous COVID-19. The neutralizing Ab response induced by the vaccine in healthy participants was similar to that triggered in participants with underlying medical conditions associated with an increased risk of severe COVID-19. ARVAC_Bivalent induced high seroconversion rates (&gt;90 %) against multiple variants and was superior to other ARVAC-versions. It increased neutralizing antibodies against SARS-CoV-2 variants (Ancestral, Gamma, Omicron, XBB and JN.1) and SARS-CoV-1. (<span><span>NCT05752201</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127045"},"PeriodicalIF":4.5,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microarray patch vaccines for typhoid conjugate vaccines: A global cost-effectiveness analysis","authors":"Marina Antillon ,&nbsp;Anna Verjans ,&nbsp;Fayad El Sheikh ,&nbsp;Tiziana Scarna ,&nbsp;Mercy Mvundura","doi":"10.1016/j.vaccine.2025.127055","DOIUrl":"10.1016/j.vaccine.2025.127055","url":null,"abstract":"<div><div>A novel typhoid conjugate vaccine (TCV) presentation, the microarray patch (MAP), is in early-stage development and could potentially help to increase coverage in hard-to-reach populations beyond what is being achieved with the current TCV in a vial presentation administered with a needle and syringe (TCV-N&amp;S). However, TCV-MAPs may come at a higher price per dose than TCV-N&amp;S. Our analysis evaluated the potential cost-effectiveness of TCV-MAPs alongside TCV-N&amp;S compared to TCV-N&amp;S alone.</div><div>A global extended cost-effectiveness analysis, taking a health care perspective, was conducted for 133 low- to upper-middle-income countries for a time horizon of 20 years (2033–2052). Health outcomes were expressed in disability-adjusted life years (DALYs) and costs in 2021 US dollars, both discounted at 3 %. We assumed TCV-MAP would cost 1.33 to 3 times the price of the TCV-N&amp;S vaccine. We calculated incremental cost-effectiveness ratios and evaluated them against various cost-effectiveness thresholds. For five selected countries, we conducted an additional subnational analysis to understand the potential value of a district-specific TCV-MAP implementation instead of a national rollout.</div><div>Across the 133 low- to upper-middle-income countries, national rollout of TCV-MAPs could avert an additional 5.2 million cases, 47,000 deaths, and 2.4 million DALYs compared to TCV-N&amp;S only, at an additional cost of US$3.5 billion over 20 years. The largest proportion of the averted burden would be in the sub-Saharan African region. TCV-MAPs could be cost-effective in 33 % of the countries but in 78 % of sub-Saharan African countries. A subnational implementation could benefit some countries for which a national implementation may not be cost-effective, averting 2–15 % of cases for less than 1–3 % of the additional cost as compared to a national rollout. MAP price was a key driver of the results.</div><div>Regional or subnational implementation, coupled with a lower price point, could significantly improve the TCV-MAP value proposition.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 127055"},"PeriodicalIF":4.5,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study","authors":"Katia Alves,&nbsp;Alex Kouassi,&nbsp;Joyce S. Plested,&nbsp;Raj Kalkeri,&nbsp;Katherine Smith,&nbsp;Muneer Kaba,&nbsp;Joy Nelson,&nbsp;Mingzhu Zhu,&nbsp;Shane Cloney-Clark,&nbsp;Zhaohui Cai,&nbsp;Raburn M. Mallory,&nbsp;Fernando Noriega,&nbsp;on behalf of the 2019nCoV-313 Study Investigators","doi":"10.1016/j.vaccine.2025.127046","DOIUrl":"10.1016/j.vaccine.2025.127046","url":null,"abstract":"<div><h3>Background</h3><div>Most of the population has been infected with SARS-CoV-2 and, thus, is primed by natural exposure. As such, it was assessed whether a single dose of the monovalent XBB.1.5 vaccine, NVX-CoV2601, elicited a comparable immune response to XBB.1.5 in seropositive unvaccinated participants to that in previously vaccinated participants, thereby allowing the former to forego a two-dose primary series.</div></div><div><h3>Methods</h3><div>In this phase 2/3, open-label, single-arm study (2019nCoV-313/NCT05975060 [group 2]), vaccine-naive participants ≥18 years with previous SARS-CoV-2 infection received one dose of NVX-CoV2601. This analysis compared the 28-day immunogenicity and safety of NVX-CoV2601 in vaccine-naive and previously vaccinated (≥3 prior mRNA-based vaccines, from 2019nCoV-313 group 1) participants. Noninferiority of neutralizing antibody (nAb) response in vaccine-naive versus vaccinated participants was the primary objective. The day-28 geometric mean titer (GMT) ratio (GMTR) and seroresponse rate (SRR; percentage of participants with a ≥4-fold rise in antibody response from baseline) were measured, and safety was assessed.</div></div><div><h3>Results</h3><div>Of the participants enrolled from September 11 to November 15, 2023, per-protocol sets included 306/338 (90.5%) vaccine-naive and 309/332 (93.1%) vaccinated participants. At day 28, adjusted GMTs (95% CI) against XBB.1.5 in the vaccine-naive and vaccinated groups were 1491.5 (1277.5–1741.4) and 841.4 (723.9–978.0), respectively. The vaccine-naive–vaccinated nAb GMTR was 1.8 (95% CI 1.43–2.20) and SRRs were 74.3% and 64.3% for vaccine-naive and vaccinated participants, respectively (SRR difference: 10.0 [95% CI 2.6–17.4]). No new safety signals or events of special interest were reported.</div></div><div><h3>Conclusions</h3><div>A single dose of NVX-CoV2601 in vaccine-naive participants with a history of SARS-CoV-2 infection elicited a robust neutralizing antibody response that was noninferior to that observed in vaccinated participants. The vaccine was well-tolerated. These data support the use of NVX-CoV2601 as a single dose, regardless of prior vaccination history.</div></div><div><h3>Trial registration</h3><div><span><span>NCT05975060</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127046"},"PeriodicalIF":4.5,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of electronic immunization registries and electronic logistics management information systems in four low-and middle-income countries: Guinea, Honduras, Rwanda, and Tanzania","authors":"C. Mantel ,&nbsp;C. Hugo ,&nbsp;C. Federici ,&nbsp;N. Sano ,&nbsp;S. Camara ,&nbsp;E. Rodriguez ,&nbsp;L. Castillo ,&nbsp;J. Condo ,&nbsp;P. Irakiza ,&nbsp;I. Sabi ,&nbsp;E. Nyanda ,&nbsp;W. Olomi ,&nbsp;M. Cavazza ,&nbsp;V. Mangiaterra ,&nbsp;M. Verykiou ,&nbsp;E. Ferenchick ,&nbsp;A. Torbica ,&nbsp;T. Cherian ,&nbsp;S. Malvolti","doi":"10.1016/j.vaccine.2025.127066","DOIUrl":"10.1016/j.vaccine.2025.127066","url":null,"abstract":"<div><h3>Background</h3><div>There is increasing interest in low-and middle-income countries (LMICs) to introduce and scale-up digital health tools like electronic immunization registries (eIR), and electronic logistics management information systems (eLMIS) to support immunization services. An evaluation of the use of these tools was conducted in four LMICs to inform decisions about their further expansion and investments.</div></div><div><h3>Methods</h3><div>Purposive sampling of regions, districts, and health facilities was done in each country based on predefined criteria. Primary data were collected between October 2021 and September 2022 in 50 health facilities in Guinea, 88 in Honduras, 36 in Rwanda, and 101 in Tanzania using semi-structured questionnaires, standardized competency assessments and data accuracy checks. Data focused on electronic tool usage, user experience, infrastructure, workforce needs, and decision-making, as well as immunization data quality and perceptions of health workers and vaccine recipients. Data analysis combined both quantitative and qualitative methods.</div></div><div><h3>Findings</h3><div>The implementation of eIR and eLMIS was associated with improvements in National Immunization Programme (NIP) processes and outcomes. Users were satisfied with the tools (87 % satisfaction rate), and 95 % of users in the African countries valued the accessibility of information, with 91 % finding it accurate and complete. Some caregivers reported better organization and shorter waiting times in health facilities using the tools. Most eIR users noted improvements in process efficiencies (81 %) and immunization service delivery (89 %). In Rwanda and Tanzania data accuracy was higher in exclusively paper or electronic settings (60 %) compared to dual paper-electronic systems (45 %). eLMIS use was associated with improvements in vaccine stock data quality and reduced stock-outs. While 77 % of health workers were digitally literate, inadequate digital infrastructure was a key barrier to tool use. Interoperability with the Civil Registration and Vital Statistics system (CRVS) was limited, hindering the tracking of unimmunized children.</div></div><div><h3>Conclusions</h3><div>To fully realize the potential of electronic tools in LMICs, full government ownership, targeted infrastructure investments, migration to fully electronic systems, and the integration of eIR with the CRVS will be essential.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127066"},"PeriodicalIF":4.5,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to, “Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey” [Vaccine (2024) Dec 2 42(26) 126437]","authors":"Amanda L. Eiden ,&nbsp;Sheila Drakeley ,&nbsp;Kushal Modi ,&nbsp;deMauri S. Mackie ,&nbsp;Alexandra Bhatti ,&nbsp;Anthony DiFranzo","doi":"10.1016/j.vaccine.2025.127054","DOIUrl":"10.1016/j.vaccine.2025.127054","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 127054"},"PeriodicalIF":4.5,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}